A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
ORGANIZATION
Keidanren Calls for Review of Japan's Unique Pharmaceutical Regulations
Japan’s biggest business lobby Keidanren has unveiled its FY2024 regulatory reform request, in which it points out that the country’s unique pharmaceutical regulations serve as barriers to drug development and clinical trials, calling for the revisiting of relevant rules. The…
To read the full story
ORGANIZATION
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
- Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
- FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
January 7, 2025
- 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
January 7, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…